Literature DB >> 24745678

CD30 in systemic mastocytosis.

Bjorn van Anrooij1, Philip M Kluin2, Joanne N G Oude Elberink1, Johanna C Kluin-Nelemans3.   

Abstract

CD30 is a transmembrane receptor, normally not expressed by mast cells, which regulates proliferation/apoptosis and antibody responses. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis. This article highlights the expression profile and role of CD30 and CD30L in physiologic and pathologic conditions, the applicability of CD30 as a marker for systemic mastocytosis, the consequences of mast cell-expressed CD30, and the possibility of future anti-CD30 based cytoreductive therapies. Crown
Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD153; CD30; CD30 ligand; Soluble CD30; Systemic mastocytosis

Mesh:

Substances:

Year:  2014        PMID: 24745678     DOI: 10.1016/j.iac.2014.01.006

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  6 in total

1.  A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Authors:  Jason Gotlib; John H Baird; Tracy I George; Cheryl Langford; Isabel Reyes; Justin Abuel; Cecelia Perkins; Kurt Schroeder; Prithviraj Bose; Srdan Verstovsek
Journal:  Blood Adv       Date:  2019-08-13

Review 2.  Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.

Authors:  Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

3.  Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Authors:  Katharina Blatt; Sabine Cerny-Reiterer; Juliana Schwaab; Karl Sotlar; Gregor Eisenwort; Gabriele Stefanzl; Gregor Hoermann; Matthias Mayerhofer; Mathias Schneeweiss; Sylvia Knapp; Thomas Rülicke; Emir Hadzijusufovic; Karin Bauer; Dubravka Smiljkovic; Michael Willmann; Andreas Reiter; Hans-Peter Horny; Peter Valent
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

4.  Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.

Authors:  Lanshan Huang; Sa A Wang; Sergej Konoplev; Carlos E Bueso-Ramos; Beenu Thakral; Roberto N Miranda; Elias Jabbour; L Jeffrey Medeiros; Rashmi Kanagal-Shamanna
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

5.  New Biomarkers of Hymenoptera Venom Allergy in a Group of Inflammation Factors.

Authors:  Kacper Packi; Joanna Matysiak; Eliza Matuszewska; Anna Bręborowicz; Zdzisława Kycler; Jan Matysiak
Journal:  Int J Environ Res Public Health       Date:  2021-04-11       Impact factor: 3.390

6.  IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

Authors:  K Bauer; E Hadzijusufovic; S Cerny-Reiterer; G Hoermann; M Reifinger; A Pirker; P Valent; M Willmann
Journal:  Vet Comp Oncol       Date:  2016-08-09       Impact factor: 2.613

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.